Biosimilars

Interim results from the phase 3 TROIKA trial demonstrate clinical equivalence between the biosimilar HD201 and trastuzumab reference in terms of efficacy, safety, pharmacokinetics, and immunogenicity in patients with HER2-positive early breast cancer.

Real-world data indicate the efficacy and safety profile of the biosimilar trastuzumab-dttb + pertuzumab was consistent with that previously reported for trastuzumab reference + pertuzumab in patients with HER2-positive breast cancer.

A biosimilar is a “highly similar” copy of a biologic drug, but it is not a generic. This definition understandably causes confusion among oncology patients and providers alike, but it is an important distinction, according to Jim Koeller, MS, professor at The University of Texas at Austin.